VEGFA and metastatic malignant neoplasm: A number of VEGF inhibitors (bevacizumab, ramucirumab and rituximab), VEGF-R-fusion proteins (aflibercept) and VEGF-R-TKI-inhibitors (sunitinib, sorafenib, vandetanib, pazopanib, regorafenib and axitinib) are currently in use for the treatment of metastatic cancers [13,14,15].